5
Clinical Trials associated with BAT-4406FA Phase II/III Study to Evaluate the Efficacy and Safety of BAT4406F Injection in Patients With Neuromyelitis Optica Lineage Disease
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study, to investigate the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica lineage disease (NMOSD) who are positive for aquaporin 4 antibody (AQP4-IgG) .
一项评价BAT4406F注射液在视神经脊髓炎谱系疾病患者中的有效性和安全性的II/III期临床研究
[Translation] A Phase II/III clinical study evaluating the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica spectrum disorder
主要研究目的:观察BAT4406F注射液在视神经脊髓炎谱系疾病患者中的有效性。
次要研究目的:1.观察BAT4406F注射液在视神经脊髓炎谱系疾病患者中的安全性;2.研究BAT4406F的药效学和药代动力学特征;3.研究BAT4406F注射液的免疫原性。
[Translation] Primary study objectives: To observe the effectiveness of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.
Secondary study objectives: 1. To observe the safety of BAT4406F injection in patients with neuromyelitis optica spectrum disorders; 2. To study the pharmacodynamic and pharmacokinetic characteristics of BAT4406F; 3. To study the immunogenicity of BAT4406F injection.
A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders
This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.
100 Clinical Results associated with BAT-4406F
100 Translational Medicine associated with BAT-4406F
100 Patents (Medical) associated with BAT-4406F
100 Deals associated with BAT-4406F